{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Post-', 'SCR\u00b3', 'Randomized Treatment Period', 'treatment', 'Period', 'RNDb', 'EOTO', 'EOS', 'Week', '-4 (1)', '0', '2', '4', '6', '8', '10', '12', '14', '16', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '56', '60', '64', 'Visite', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'EQ-5D-Y for children', 'Patient Reported Outcomes (Caregiver)', 'PACQLQ (for caregivers of patients >7', 'years old at Randomization V2)', 'PK, PD, Pharmacogenetics', 'Blood biomarkers/', 'Total IgE, and antigen-specific IgES', 'Antigen-specific lgG4 panel', 'Systemic drug concentration', 'Exhaled NO u', 'X', 'Safety Assessments', 'Total lgG, IgG subclasses, IgM, IgA', 'Anti-drug antibodiesW', 'Pregnancy test for girls who are', 'menstruatingX', 'Prior and concomitant medications', 'AE/SAE recording', 'Clinical lab testingy', '(hematology/biochemistry)', 'Urinalysis', 'ECG', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 22']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Post-', 'SCR\u00b3', 'Randomized Treatment Period', 'treatment', 'Period', 'RNDb', 'EOTO', 'EOS', 'Week', '-4 (1)', '0', '2', '4', '6', '8', '10', '12', '14', '16', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '56', '60', '64', 'Visite', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'Vaccines Record Review /', 'Scheduling2,da', 'Any planned vaccination for tetanus,', 'X\u00b2', 'diphtheria, pertussis\u00b2', 'Any planned vaccination for seasonal', 'X\u00b2', 'trivalent / quadrivalent influenza\u00b2', 'Blood sample collectionaa', 'for', 'assessment of IgG response to', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'vaccination', 'AE: Adverse event; AESI: Adverse Events of Special Interest ; EQ-5D-Y: EuroQol 5-dimensions questionnaire for children; ETD: early treatment discontinuation visit; FEV1: Forced expiratory volume in 1 second; HRQol:', 'health-related quality of life; IgA: Immunoglobulin A; IgE: IgG: Immunoglobulin E; Immunoglobulin G; IgM: Immunoglobulin M; IVRS: Interactive voice response system; IWRS: Interactive web response system, NO: Nitric', 'oxide; ACQ-IA: Asthma Control Questionnaire-Interviewer Administered; PACQLQ: Pediatric Asthma Caregivers Quality of Life Questionnaire; PAQLQ(S)-IA: Pediatric Asthma Quality of Life Questionnaire With', 'Standardised Activities-Interviewer Administered; PD: Pharmacodynamics; PK: Pharmacokinetics; PRQLQ-IA: Pediatric Rhinoconjunctivitis Quality of Life Questionnaire-Interviewel Administered; PEF: Peak expiratory', 'flow; SAE: Serious adverse event;', 'a The Screening Period is 4+1 weeks (21-35 days) in duration to collect baseline data on asthma control and assure eligibility criteria. Prior to and during the Screening Period, patients must be on one of the', 'following: stable-dose background therapy of medium-dose inhaled corticosteroid (ICS) with second controller medication (ie, long-acting \u00df2 agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting', 'muscarinic antagonist (LAMA), or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller, for at least 3 months with a stable dose 1 month prior to Screening Visit 1.', 'b Randomization Visit (Visit 2) is defined as Day 1. The randomization will be stratified by eosinophil count (<300 cells/ L and >300 cells/L) and stable dose-level of ICS (medium/high) at Screening, and by', 'region.', 'C Patients who permanently discontinue the study medication will be asked and encouraged to return to the clinic for study visits and participate in assessments according to the visit schedule until the end of the', 'study (EOS) with a +5 day window or up to recovery or stabilization of any adverse event. At the time of permanent treatment discontinuation, patients will perform the early treatment discontinuation (ETD) visit', 'with all the assessments defined for the end-of-treatment (EOT) Visit 28. However, patients who discontinue early from treatment will not be eligible for the 1-year long-term extension study.', 'For patients who permanently discontinue the study, under exceptional circumstances where there is no possibility for a patient and parent(s)/caregiver(s)/legal guardian(s) to come to the site for the scheduled', \"follow-up visit, a phone contact may be made after Sponsor's approval is given. During that phone contact, at least information about adverse events (AEs), concomitant medication and asthma exacerbation\", 'events must be collected, and the schedule for these calls should still reflect the visit schedule.', 'Patients who discontinue early from treatment may be asked to return to the clinic to have additional ADA samples collected for analysis based on the overall assessment of antibody titers and clinical presentation', 'at the time of discontinuation.', 'd Eligible patients who complete the Randomized Treatment Period will be offered the opportunity to participate in the 1-year long-term extension study with dupilumab. Patients subsequently enrolled in the 1-year', 'long-term extension study will not participate in the post-treatment period of this trial.', 'e The visit windows for all subsequent visits post-randomization on Day 1 will be 3 days during the treatment period and =5 days during the post-treatment period.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 23']\n\n###\n\n", "completion": "END"}